The aim of this study was to compare the action of fenofibrate on monocyte cytokine release
between patients with isolated mixed dyslipidemia and dyslipidemia coexisting …

OBJECTIVE: To examine the effects of fenofibrate (160mg/d) therapy on fasting and
postprandial cytokine production in subjects with metabolic syndrome and …

Context: Apart from lowering lipid levels, peroxisome proliferator-activated receptor (PPAR)
α activators (fibrates) produce many other favorable effects that may contribute to their …

Background Fibrates were found to reduce cytokine release and low-grade inflammation in
patients with impaired glucose tolerance. The aim of this study was to investigate whether …

This study assessed the effect of bezafibrate on monocyte secretory function and systemic
inflammation in patients with impaired fasting glucose (IFG), comparing this effect with that …

Fibrates and omega‐3 fatty acids have been used for many years in the treatment of
increased triglyceride levels. Unfortunately, pleiotropic effects of these agents in patients …

Since atherosclerosis has been proven to be an inflammatory disease, it is obvious that the
proper treatment for dyslipidemia should not only correct lipid parameters but also inhibit …

This study evaluated the postprandial (PP) response to an oral fat load in 28 male patients
with type 2 diabetes (mean HbA1c of 5.1%), all receiving metformin and performing physical …

Our study aimed to compare the effect of fenofibrate on hemostasis between patients with
isolated impaired fasting glucose (IFG) and isolated mixed dyslipidemia and to examine the …

Background Type 2 diabetes is associated with early development of endothelial
dysfunction. Patients present with typical dyslipidemia (predominantly high levels of …